BACKGROUND: This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. DESIGN AND METHODS: Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. RESULTS: At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P<0.001; 27.7 versus 12.0 months, P<0.001; not reached versus 44.2 months, P=0.021, respectively). The benefit of a complete or very good partial response was independent of when it was achieved. CONCLUSIONS: Continuing treatment with lenalidomide plus dexamethasone to achieve best response, in the absence of disease progression and toxicity, provided deeper remissions and greater clinical benefit over time for patients in this study.
BACKGROUND: This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. DESIGN AND METHODS: Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. RESULTS: At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P<0.001; 27.7 versus 12.0 months, P<0.001; not reached versus 44.2 months, P=0.021, respectively). The benefit of a complete or very good partial response was independent of when it was achieved. CONCLUSIONS: Continuing treatment with lenalidomide plus dexamethasone to achieve best response, in the absence of disease progression and toxicity, provided deeper remissions and greater clinical benefit over time for patients in this study.
Authors: D O'Shea; C Giles; E Terpos; J Perz; M Politou; V Sana; K Naresh; I Lampert; D Samson; S Narat; E Kanfer; E Olavarria; J F Apperley; A Rahemtulla Journal: Bone Marrow Transplant Date: 2006-04 Impact factor: 5.483
Authors: Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej Jakubowiak; William Dalton; Anthony Boral; Dixie-Lee Esseltine; David Schenkein; Kenneth C Anderson Journal: Blood Date: 2007-08-09 Impact factor: 22.113
Authors: Paul G Richardson; Robert L Schlossman; Edie Weller; Teru Hideshima; Constantine Mitsiades; Faith Davies; Richard LeBlanc; Laurence P Catley; Deborah Doss; Kathleen Kelly; Mary McKenney; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Rebecca Rich; Joan J Ryoo; Dharminder Chauhan; Kathe Balinski; Jerome Zeldis; Kenneth C Anderson Journal: Blood Date: 2002-11-01 Impact factor: 22.113
Authors: B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar Journal: Leukemia Date: 2006-07-20 Impact factor: 11.528
Authors: Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert L Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson Journal: Blood Date: 2006-07-13 Impact factor: 22.113
Authors: M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille Journal: N Engl J Med Date: 1996-07-11 Impact factor: 91.245
Authors: Paul G Richardson; Edie Weller; Sundar Jagannath; David E Avigan; Melissa Alsina; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; Irene M Ghobrial; Deborah Doss; Diane L Warren; Laura E Lunde; Mary McKenney; Carol Delaney; Constantine S Mitsiades; Teru Hideshima; William Dalton; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson Journal: J Clin Oncol Date: 2009-09-28 Impact factor: 44.544
Authors: Martha Q Lacy; Morie A Gertz; Angela Dispenzieri; Suzanne R Hayman; Susan Geyer; Brian Kabat; Steven R Zeldenrust; Shaji Kumar; Philip R Greipp; Rafael Fonseca; John A Lust; Stephen J Russell; Robert A Kyle; Thomas E Witzig; P Leif Bergsagel; A Keith Stewart; S Vincent Rajkumar Journal: Mayo Clin Proc Date: 2007-10 Impact factor: 7.616
Authors: J Bladé; D Samson; D Reece; J Apperley; B Björkstrand; G Gahrton; M Gertz; S Giralt; S Jagannath; D Vesole Journal: Br J Haematol Date: 1998-09 Impact factor: 6.998
Authors: Paul G Richardson; Sundar Jagannath; Philippe Moreau; Andrzej J Jakubowiak; Marc S Raab; Thierry Facon; Ravi Vij; Darrell White; Donna E Reece; Lotfi Benboubker; Jeffrey Zonder; L Claire Tsao; Kenneth C Anderson; Eric Bleickardt; Anil K Singhal; Sagar Lonial Journal: Lancet Haematol Date: 2015-11-16 Impact factor: 18.959
Authors: Bruno Paiva; Mauricio Chandia; Noemi Puig; Maria-Belen Vidriales; Jose J Perez; Lucia Lopez-Corral; Enrique M Ocio; Ramon Garcia-Sanz; Norma C Gutierrez; Ana Jimenez-Ubieto; Juan-José Lahuerta; Maria-Victoria Mateos; Jesús F San Miguel Journal: Haematologica Date: 2014-11-07 Impact factor: 9.941
Authors: Neil Majithia; S Vincent Rajkumar; Martha Q Lacy; Francis K Buadi; Angela Dispenzieri; Morie A Gertz; Suzanne R Hayman; David Dingli; Prashant Kapoor; Lisa Hwa; John A Lust; Stephen J Russell; Ronald S Go; Robert A Kyle; Shaji K Kumar Journal: Am J Hematol Date: 2015-10-06 Impact factor: 10.047